Macular Degeneration and World Sight Day 2026: What South Africans Should Know Before 8 October

Thursday, 8 October 2026 is World Sight Day, this year built around the theme “#LoveYourEyes,” and feeding into a Global Summit for Eye Health taking place in November. It’s a useful deadline to work backward from. If there’s one eye condition worth understanding properly before that date, it’s age-related macular degeneration (AMD), the leading cause of irreversible vision loss in people over 50 worldwide, and a condition that 2026’s research and treatment developments are reshaping faster than almost any other area of eye care.

What AMD actually is

Macular degeneration affects the macula, the small, densely packed area at the centre of the retina responsible for sharp, detailed central vision — the kind you use for reading, recognising faces, and driving. Peripheral vision is usually untouched, which is exactly why AMD is so disruptive: patients don’t go blind in the everyday sense, but the vision they rely on most for daily life gradually blurs, distorts, or develops a blank patch right where they’re looking.

There are two forms. Dry AMD, the more common type, progresses slowly as the macula thins over years. Wet AMD is less common but far more aggressive, driven by abnormal blood vessels growing beneath the retina that leak fluid and blood, and it can cause serious vision loss within weeks if untreated. Both forms share the same early warning sign: straight lines that start to look wavy or bent, most easily checked at home with a simple grid pattern called an Amsler chart.

Why this matters for South Africa right now

South Africa is getting older, and the numbers from Statistics South Africa’s most recent population estimates are worth sitting with: the number of people aged 60 and over grew from 3.6 million (7.7% of the population) in 2002 to 6.6 million (10.5%) in 2025, driven by declining fertility, longer life expectancy, and improving living conditions. AMD risk climbs steeply with age, so a country with a growing older population is, almost by definition, a country that will be managing more macular degeneration in the years ahead.

There’s an important nuance worth being upfront about, because it’s easy to assume every eye condition disproportionately affects the same group. Unlike glaucoma, which population studies consistently show is markedly more common and more aggressive in people of African ancestry (something we covered in detail a few weeks ago), large studies including the Baltimore Eye Survey and the Multi-Ethnic Study of Atherosclerosis have found AMD is generally less prevalent in Black African populations than in white populations. Genetic research published this year adds useful detail here too: the specific genes driving AMD risk actually differ by ancestry, which is pushing the field toward more personalised risk assessment rather than one-size-fits-all screening advice. None of this makes AMD irrelevant locally — South Africa’s white population has the fastest-rising aging index of any group in the country, and AMD still occurs, and still matters, across every population group, particularly once other risk factors like smoking, high blood pressure, high cholesterol, and heavy lifetime UV exposure are added to the picture. It does mean the honest, useful message is “know your personal risk,” not a blanket claim that doesn’t hold up.

One number that cuts across all of this: AMD is recognised as a Prescribed Minimum Benefit condition in South Africa, meaning medical schemes are required to fund its treatment. That’s a meaningful protection, but it only helps once the diagnosis has actually been made.

What’s new in AMD care in 2026

Gene therapy edging toward a single-treatment future. Data presented at the American Society of Retina Specialists’ 2026 meeting in July showed 4D-150, an investigational gene therapy given as a single in-office injection, dramatically reducing how often wet AMD patients need repeat anti-VEGF injections. In patients treated within three months of diagnosis, 87% went two full years without needing another injection while maintaining their vision and retinal health. Across the wider study group, two-thirds to 69% needed two or fewer injections over that same two-year period, with a favourable safety record through four years of follow-up. For a disease historically managed with injections every four to eight weeks indefinitely, that’s a genuine shift in treatment burden.

The first real treatments for geographic atrophy. Until recently, advanced dry AMD (geographic atrophy) had no approved treatment at all — patients were simply monitored as vision worsened. Pegcetacoplan and avacincaptad pegol, now established treatment options, are the first therapies shown to slow the progression of this advanced form of dry AMD, opening a treatment pathway that didn’t exist a few years ago.

AI-powered home monitoring between visits. FDA-authorised home OCT devices now let patients being treated for wet AMD scan their own retinas at home, with AI analysis flagging fluid changes that might need earlier attention, closing the gap between quarterly or monthly clinic visits rather than relying solely on symptoms or the next scheduled appointment.

Who should be screened, and how often

Everyone should have a baseline, dilated retinal examination by age 50, even with no symptoms and no family history. From 60 onward, an annual comprehensive eye exam that includes retinal imaging is the standard recommendation. That schedule should move earlier and more frequent if you smoke, have high blood pressure or high cholesterol, have a family history of AMD, or have already been diagnosed with early-stage disease, in which case six-to-twelve-month monitoring is typical. Between appointments, an Amsler grid check at home — ask us for a printed copy — takes under a minute and can catch a change worth acting on before your next scheduled visit.

What this means for your next eye examination

At Jason Stander Optometrists, a comprehensive eye exam for anyone over 50 includes a dilated retinal assessment as standard, because with AMD, as with so much in eye care, the goal is catching change before it’s noticed rather than after. With World Sight Day landing on 8 October, it’s a fitting few weeks to get that check done rather than let it slide into next year.

Book a comprehensive eye examination with our team at Shop 7, Cycad Centre, Bendor, Polokwane. If you’re over 50, have a family history of macular degeneration, or simply can’t remember your last retinal check, make World Sight Day 2026 the reason you finally book it.